Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00432-019-03012-z.pdf
Reference35 articles.
1. Bando H (2017) The current status and problems confronted in delivering precision medicine in Japan and Europe. Curr Probl Cancer 41:166–175. https://doi.org/10.1016/j.currproblcancer.2017.02.003
2. Barlesi F et al (2014) Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 25:1044–1052. https://doi.org/10.1093/annonc/mdu098
3. Comprehensive genomic characterization of squamous cell lung cancers (2012) Nature 489:519-525 https://doi.org/10.1038/nature11404
4. Einhorn LH (2008) First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 26:3485–3486. https://doi.org/10.1200/jco.2008.17.2056
5. Facchinetti F, Aldigeri R, Aloe R, Bortesi B, Ardizzoni A, Tiseo M (2015) CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients. Tumour Biol 36:5943–5951. https://doi.org/10.1007/s13277-015-3269-6
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes;Life;2023-05-31
2. Primary tumor type prediction based on US nationwide genomic profiling data in 13,522 patients;Computational and Structural Biotechnology Journal;2023
3. Genetic Variants of CLEC4E and BIRC3 in Damage-Associated Molecular Patterns-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival;Frontiers in Oncology;2021-10-06
4. Correction to: Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified;Journal of Cancer Research and Clinical Oncology;2021-07-23
5. How should we manage non-small-cell lung cancer “not-otherwise-specified”?;Medical Oncology;2021-06-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3